Results 21 to 30 of about 36,968 (260)

Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background We examined the impact of bisphosphonates as adjuvant therapy on the recurrence of giant cell bone tumors and the impact of various tumor stages and surgical techniques on this effect.
Marwa Mohsen, Hasnaa Osama, Mina Nicola, Haitham Saeed, Mohamed E. A. Abdelrahim   +4 more
doaj   +1 more source

Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. [PDF]

PLoS ONE, 2011
BACKGROUND: Bisphosphonates and parathyroid hormone (PTH) represent the antiresorptive and anabolic classes of drugs for osteoporosis treatment. Bone mineral density (BMD) is an essential parameter for the evaluation of anti-osteoporotic drugs.
Longxiang Shen, Xuetao Xie, Yan Su, Congfeng Luo, Changqing Zhang, Bingfang Zeng   +5 more
doaj   +1 more source

Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta

Journal of Children's Orthopaedics, 2011
Introduction Bisphosphonates are currently the medical treatment most often used in children with osteogenesis imperfecta (OI). The purpose of this retrospective pre–post study was to evaluate the efficacy of treatment with bisphosphonates.
F. de Graaff, W. Verra, J. E. H. Pruijs, R. J. B. Sakkers   +3 more
doaj   +1 more source

Osteonecrose da mandíbula associada a bifosfonatos intravenosos em doentes oncológicos.

Acta Médica Portuguesa, 2008
Bisphosphonates are synthetic analogs of inorganic pyrophosphate, which are not only potent inhibitors of osteoclast-mediated bone resorption, but also present an important inhibitory activity of angiogenesis.
Ana Carvalho, Rui Amaral Mendes, Davide Carvalho, João F C Carvalho   +3 more
doaj   +1 more source

Therapeutic potential of bisphosphonates - review of medical indications, mechanism of action, interactions and adverse effects

Journal of Education, Health and Sport
Introduction: Bisphosphonates are pharmacological agents that inhibit bone resorption by targeting osteoclasts, thereby increasing bone density and reducing fracture risk.
Agnieszka Mikosińska, Mateusz Litwin, Jakub Parys, Patrycja Kałuziak, Aleksandra Witek, Martyna Kaźmierczak, Stanisław Jesionek, Marta Jajczak, Maciej Mossakowski   +8 more
doaj   +1 more source

BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAWS AND CURRENT THERAPIES

Cumhuriyet Dental Journal, 2017
Bisphosphonates are pharmacological agents which are the potent inhibitors of osteoclastic activity. Nowadays, bisphosphonates are used to treat a variety of bone disease or related complications such as metastatic or osteolytic bone disease ...
Damla Torul, Mehmet Cihan Bereket
doaj   +1 more source

Oral Mucosal Ulcer Associated with Improper Usage of Bisphosphonate: A Case Report

Türk Osteoporoz Dergisi, 2023
Bisphosphonates are widely used agents for osteoporosis. Although bisphosphonates are generally well-tolerated drugs, especially oral forms may have gastrointestinal system side effects.
Şeyma Nur Bayındır, Bilinç Doğruöz Karatekin, Afitap İçağasıoğlu   +2 more
doaj   +1 more source

ATYPICAL FRACTURES DUE TO LONG TREATMENT WITH BISPHOSPHONATES (CRITICAL REVIEW)

Travmatologiâ i Ortopediâ Rossii, 2013
This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. A PubMed search of literature was performed.
G. S. Golubev
doaj   +1 more source

Bisphosphonates and osteonecrosis of jaws

Journal of Indian Academy of Oral Medicine and Radiology, 2012
Bisphosphonates are used to treat osteoporosis. Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms- In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in ...
Geetha Vijay, Vijay Raghavan
doaj   +1 more source

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication

Saudi Pharmaceutical Journal, 2018
Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs.
Bander Balkhi, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio   +2 more
doaj   +1 more source